NCT07095465Phase 3Recruiting

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-02Estimated
Enrollment · participants126Estimated
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Enrolling by invitation. After: Recruiting.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Enrolling by invitation.

Check registry source